New FDA Approvals: FDA Issues Emergency Use Authorization to Kineret

fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
December 8

Nov. 9: The FDA issued an emergency use authorization to Amgen Inc.’s Kineret (anakinra) for the treatment of COVID-19 in hospitalized adults with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). The agency initially approved the interleukin-1 receptor antagonist (IL-1Ra) on Nov. 14, 2001. The recommended dosing for this latest use is 100 mg administered daily by subcutaneous injection for 10 days. Drugs.com lists the price of one 100 mg prefilled syringe as more than $1,265.

0
0 Comments
© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
February 10

New FDA Approvals: FDA Grants Additional Indication to Rinvoq

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
October 13

New FDA Approvals: FDA Approves Sotyktu

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
September 8

New FDA Approvals: FDA Converts Accelerated Approval to Full for Tabrecta

READ MORE

The Latest

Premium Categories

enhance-patient-assistance-programs

Meet Our Reporters

Tags

Cell and Gene TherapiesCOVIDDrug ApprovalsFDAOncologySpecialty Drugs

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today